Pavlovic, Blaz
Bräutigam, Konstantin
Dartiguenave, Florence
Martel, Paul
Rakauskas, Arnas
Cesson, Valérie
Veit, Markus
Oechslin, Pascal
Gu, Alexander
Hermanns, Thomas
Saba, Karim
Poyet, Cédric
Hötker, Andreas M.
Rupp, Niels J.
Valerio, Massimo
Derré, Laurent
Eberli, Daniel
Banzola, Irina
Funding for this research was provided by:
Innosuisse - Schweizerische Agentur für Innovationsförderung (40242.1 IP-LS)
Universität Zürich (MEDEF 20018)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (40B1-0_203684/1)
Article History
Received: 5 December 2023
Accepted: 18 July 2024
First Online: 5 August 2024
Competing interests
: Patents: This study was submitted for patent application (applicant: University of Zürich; inventors: I. Banzola, N. Alijaj, B. Pavlovic, D. Eberli). The patent application was submitted to the European patent office (application number: PCT/EP2022/086491). Conflicts of interest: N.J.R. discloses an advisory board function and receipt of honoraria from F. Hoffmann-La Roche AG. This study was submitted for patent application (applicant: University of Zürich; inventors: I. Banzola, N. Alijaj, B. Pavlovic, D. Eberli). The patent application was submitted to the European patent office (PCT/EP2022/086491). I. Banzola is founder and CEO of ONtrack Biomedical AG, a spin-off company of the University of Zurich and University Hospital Zurich, dedicated to developing PCa diagnostics. D. Eberli is also a founder of ONtrack Biomedical AG. Other authors do not have any conflict of interest.